Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer

PURPOSE: Our previous works demonstrated the ability of metformin to revert resistance to gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in non-small-cell lung cancer (NSCLC) EGFR/LKB1 wild-type (WT) cell lines. However, the optimal dose of metformin to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgillo, Floriana, Fasano, Morena, Della Corte, Carminia Maria, Sasso, Ferdinando Carlo, Papaccio, Federica, Viscardi, Giuseppe, Esposito, Giovanna, Di Liello, Raimondo, Normanno, Nicola, Capuano, Annalisa, Berrino, Liberato, Vicidomini, Giovanni, Fiorelli, Alfonso, Santini, Mario, Ciardiello, Fortunato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ESMO Open 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519802/
https://www.ncbi.nlm.nih.gov/pubmed/28761738
http://dx.doi.org/10.1136/esmoopen-2016-000132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519802/
https://www.ncbi.nlm.nih.gov/pubmed/28761738
http://dx.doi.org/10.1136/esmoopen-2016-000132

Ejemplares similares